Nanocurcumin role in patients with breast and gastrointestinal cancer resistant to treatment

Nanocurcumin role as an adjunctive therapy on treatment response and quality of life in patients with breast and gastrointestinal cancer resistant to treatment: Randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014091418745N2

Enrollment

Registered

2014-10-09

Start date

2014-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast and GI cancers. Breast, unspecified

Interventions

Intervention 1: 12 tablet of nanocurcumin placebo per a day (3 tablet, QID) for three months except during chemotherapy. Intervention 2: 12 tablet of nanocurcumin per a day (3 tablet, QID) for three m

Placebo

Treatment - Drugs

12 tablet of nanocurcumin placebo per a day (3 tablet, QID) for three months except during chemotherapy

12 tablet of nanocurcumin per a day (3 tablet, QID) for three months except during chemotherapy

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Randomize; Pathology report of invasive breast and GI carcinoma; signed informed consent; resistant to treatment; metastatic disease. Exclusion criteria: Less than 50% heart ejection fraction; heart failure; liver failure (liver enzymes more than 5 times of upper normal limit) or creatinine more than 2 mg/dl; low albumin<2; brain metastasis; sever diarrhea.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Response to treatment. Timepoint: Before and after drug therapy, 3 months. Method of measurement: CT scan.	—

Secondary

Measure	Time frame
The assesment of quality of life. Timepoint: Befor and after of treatment, 3 months. Method of measurement: Questionnaires of FACT and CARES.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ali Mohammad Alizadeh

Tehran University of Medical Sciences

aalizadeh@razi.tums.ac.ir+98 21 6119 2501

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026